Abstract
Hematopoietic stem cells (HSCs) supply all blood cells throughout life by making use of their self-renewal and multilineage differentiation capabilities. Over the last few years, transplantation of hematopoietic stem and progenitor cell from mobilized blood stem cells, umbilical cord blood and selected CD34+ cells has been used for treatment of patients with hematologic and non-hematologic malignances. The techniques have become available that allow the extensive proliferation, orderly differentiation, functional activation and gene transfer of hematopoietic stem/progenitor cells in ex vivo culture systems. These techniques have now developed to the point at which clinical trials are now underway in a variety of settings for the applications of hematopoietic stem cell transplantation, hematopoietic support after high-dose chemotherapy, immunotherapy of cancers, and gene therapy. The article will discuss the characteristics, detecting assays, surface markers, expansion, orderly differentiation, cell therapy and gene therapy of hematopoietic stem/progenitor cells. Except that, it will also discuss some advanced achievements of stem cell research, such as the multilineage differentiation of marrow-derived mesenchymal stem cells. Some results of different gene expression between stem cells and induced cells by gene chip analysis will be reported.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pei XT, Yan CS, Zhu JP. Kinetic changes of CFU-S in a stable or unstable liquid culture system.Acta Physiol Sinica. 1988;40:569.
Wu CT, Pei XT, Cong PJ. Effects of human fetal liver extract on the growth of HL-60 cells.Exp Hematol. 1989;17:304.
Wu CT, Wang YZ, Pei XT. Studies on the suppression of HL-60 cell growth in vitro by low molecular weight suppressor of human fetal liver origin.Leuk Res. 1989;13:825.
Pei XT, Wu CT. Preferential suppression of low molecular weight natural tumor suppressor of human fetal liver origin on the growth of leukemic cells in vitro.Exp Hematol. 1990; 18:927.
Pei XT, Wu CT, Lao MF, et al. Preliminary application of a low molecular weight tumor suppressor in purged autologous bone marrow transplantation.Cancer J. 1992;5:142.
Wu CT, Pei XT, Cao JR, et al. A new pharmacological activity of Dibutyl Phthalate (DBP) on selective elimination of tumor cells from bone marrow.Leuk Res. 1993;17:557.
Pei XT, Wu CT, Coutinho LH, et al. The effect of GM-CSF and IL-3 on the grafting efficiency of umbilical cord blood CD34+ cells.Acta Physiol Sinica 1995;47:485.
de Wynter EA, Coutinho LH, Pei X, et al. Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems.Stem Cells. 1995;13:524.
Pei XT, Wang LS, Xu L, et al. Isolation and characterization of human CD34+ hematopoietic progenitor cells by highgradient magnetic cell sorting.High Technol Letters 1995;1: 108.
Wu CT, Yang K, Pei XT, et al. Bone marrow purging with Dibutyl Phthalate — experimental basis and a preliminary clinical application.Leuk Res. 1995;19:557.
Wang LS, Wu CT, Pei XT, et al. Dibutyl Phthalate (DBP) purged autologous bone marrow transplantation in the treatment of leukemial.Leuk Res. 1996;20:343.
Wang LS, Wu CT, Pei XT, et al. Purging effect of Dibutyl Phthalate on leukemic cells associated with apoptosis.Leuk Res. 1996;20:989.
Pei Xuetao. Who is hematopoietic stem cell: CD34+ or CD34?Int J Hematol. 1999;70:213.
Du N, Pei XT, Luo CJ, et al. In vitro studies on the expression of FLT3 Ligand regulated by Egr-1 regulated sequence.Immunol J. 2000,16:166.
Author information
Authors and Affiliations
About this article
Cite this article
Pei, X. Stem cell engineering: The new generation of cellular therapeutics. Int J Hematol 76 (Suppl 1), 155–156 (2002). https://doi.org/10.1007/BF03165233
Issue Date:
DOI: https://doi.org/10.1007/BF03165233